Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 26, 2006BloodOpen Access

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

John C. ByrdJohn C. ByrdNorthwestern UniversityTLThomas S. LinJohnson & Johnson (United States)JDJames T. DaltonUniversity of Rochester Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Byrd et al. (2006) studied this question.

synapsesocial.com/papers/6a1829794f2b3115b0137bcahttps://doi.org/10.1182/blood-2006-05-020735
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 198052005 · 123 citations
  2. 2Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.1998 · 242 citations
  3. 3Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo2001 · 646 citations
  4. 4Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma2001 · 198 citations
  5. 5Flavopiridol Induces Apoptosis in Chronic Lymphocytic Leukemia Cells Via Activation of Caspase-3 Without Evidence of bcl-2 Modulation or Dependence on Functional p531998 · 282 citations